Abstract
In the field of cancer research, in vitro models are widely used to investigate tumor biology as well as new experimental treatments. There is a need to improve these models, making them more in vivo-like, in order to meet the new challenges arising together with emerging knowledge such as the discovery of cancer stem-like cells. When investigating glioblastomas in vitro – and especially the supposed cancer stem cells – three dimensional spheroid models recently came into focus. Spheroids have earlier been derived from commercial glioblastoma cell lines, but in the 1990s the spheroid model was further improved by the introduction of organotypic primary spheroids derived from small tumor fragments preserving tumor tissue characteristics including cell-to-cell interactions, extracellular matrix, macrophages and blood vessels. Most recently – in the cancer stem cell context – spheroids have been derived from single cells from dissociated primary glioblastoma tissue and cultured in serum-free conditions similar to neuronal stem cells. Using this methodology a much better preservation of cancer stem cell features was obtained compared to the use of serum-containing medium. Furthermore, in a study recently performed in our lab we demonstrated similar advantages of culturing primary organotypic spheroids in serum-free medium favoring an in-vivo-like cancer cell phenotype with better preservation of cancer stem cell features. In addition to this, more vascular structures were seen under serum-free conditions suggesting that the close relationship between blood vessels and cancer stem-like cells was better preserved in this medium. As it will be reviewed below, culturing primary spheroids in a serum-free medium adds a new level to the spheroid model suggesting that this model should be included in studies of tumor biology and drug development when possible.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Aaberg-Jessen C, Christensen K, Offenberg H, Bartels A, Dreehsen T, Hansen S, Schrøder HD, Brünner N, Kristensen BW (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95(1):117–128
Bao S, Wu Q, McLendon RE, Hao Y, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006a) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006b) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007) CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9):4010–4015
Bjerkvig R, Tønnesen A, Laerum OD, Backlund E (1990) Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neorosurg 72:463–475
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82
Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R, Kristensen BW (2010a) Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery 66(5):933–947
Christensen K, Schrøder HD, Kristensen BW (2008) CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 90:157–170
Christensen K, Schrøder HD, Kristensen BW (2010b) CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol [Epub ahead of print]
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275–284
Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD (1993) Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory an invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 53(2):209–214
Fehlauer F, Muench M, Rades D, Stalpers LJ, Leenstra S, van der Valk P, Slotman B, Smid EJ, Sminia P (2005) Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration. J Cancer Res Clin Oncol 131(11):723–732
Fuchs E, Tumbar T, Guasch G (2004) Socializing with the neighbors: stem cells and their niche. Cell 116:769–778
Gage FH, Ray J, Fisher LJ (1995) Isolation, characterization, and use of stem cells from the CNS. Annu Rev Neurosci 18:159–192
Galli R, Binda E, Orfanelli U, Cipellatti B, Gritti A, de Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19):7011–7021
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4):1710–1715
Gilbertson RJ, Rich JN (2007) Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733–736
Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115(6):1503–1521
Hermansen SK, Christensen KG, Jensen SS, Kristensen BW (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59(4):391–407
Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, Fernebro E, EORTC-Receptor and Biomarker Group (2004) Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer 40(1):64–72
Ignatowa TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39(2):193–206
Kaaijk P, Troost D, Sminia P, Hulshof MC, van der Kracht AH, Leenstra S, Bosch DA (1997) Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastomas. Eur J Cancer 33(4):645–651
Kuvaja P, Würtz SØ, Talvesaari-Mattila A, Brünner N, Pääkkö P, Turpeenniemi-Hujanen T (2007) High serum TIMP-1 correlates with poor prognosis in breast carcinoma – a validation study. Cancer Biomark 3(6):293–300
Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5):391–403
Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557
Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, Alessandri G, Marras C, Croci D, De Rossi M (2006) Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54(8):850–860
Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B (2007) Identification of SOX2 as a novel Glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 96(8):1293–1301
Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S (2004) Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304(5675):1338–1340
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire JA, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401
Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah T (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68(2):133–144
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestengarden L, Røsland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PØ (2007) CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122:761–768
Yuhas JM, Li AP, Martinez AO, Ladman AJ (1977) A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 37:3639–3643
Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14(1):123–129
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Aaberg-Jessen, C., Christensen, K., Kristensen, B.W. (2012). Primary Glioma Spheroids: Advantage of Serum-Free Medium. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 1. Stem Cells and Cancer Stem Cells, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1709-1_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-1709-1_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-1708-4
Online ISBN: 978-94-007-1709-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)